Colorado News Desk

Urothelial Carcinoma Emerging and Marketed Drugs Analysis (2023 Updates) | Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

 Breaking News
  • No posts were found

Urothelial Carcinoma Emerging and Marketed Drugs Analysis (2023 Updates) | Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

March 23
03:54 2023
Urothelial Carcinoma Emerging and Marketed Drugs Analysis (2023 Updates) | Clinical Trials Evaluation, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, about 40+ key pharma and biotech companies are working on 50+ drugs in the Urothelial Carcinoma therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

As per DelveInsight, the Urothelial Carcinoma therapeutics market is anticipated to evolve immensely in the coming years owing to the launch of upcoming therapies, increasing awareness, changing lifestyle, and the rise in the number of cases of Urothelial Carcinoma.

The Urothelial Carcinoma pipeline possesses several potential drugs that are expected to be launched in the near future. Ramucirumab (Eli Lilly), Infigratinib (QED Therapeutics), Rogaratinib (Bayer), Pemigatinib (Incyte Corporation), Sacituzumab govitecan (Immunomedics), NKTR-214 (Nektar Therapeutics/Bristol-Myers Squibb), RX-3117 (Rexahn Pharmaceuticals), are some of the emerging pipeline therapies under various stages of clinical development.

Urothelial Carcinoma Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Urothelial Carcinoma Market. 

The Urothelial Carcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Urothelial Carcinoma Pipeline Analysis

Urothelial Carcinoma Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Urothelial Carcinoma and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Urothelial Carcinoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Route of Administration

Urothelial Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Intranasal

  • Intrathecal

  • Intravenous

  • Oral

  • Oral/Intravenous

  • Parenteral

  • Subcutaneous

  • Subcutaneous/Intramuscular

  • Transdermal

Molecule Type

The report covers the emerging pipeline products that have been categorized under various Molecule types, such as

  • Antisense oligonucleotide

  • Gene therapy

  • Hormones

  • Neuropeptides

  • Oligonucleotides

  • Small Molecule

  • Triglyceride

Learn How the Ongoing Clinical & Commercial Activities will Affect the Urothelial Carcinoma Therapeutic Segment @


Urothelial Carcinoma Therapeutics Landscape

Treatment for Urothelial Carcinoma (UC) can be employed in different classes of chemotherapy, immunotherapy, radiation therapy, target-specific therapy, and surgical treatment. Metastatic Urothelial Carcinoma has shown poor survival when treated with chemotherapy; however, more alternatives are available due to the advancements in the treatment of new immunotherapies.

Development of targeted therapies for Urothelial Carcinoma is still in the early stages; consequently, there have been no major therapeutic advances to date. However, a greater understanding of urothelial carcinoma and solid tumor biology has resulted in a proliferation of clinical trials that could significantly advance treatment strategies.

Several major pharma and biotech giants are developing therapies for Urothelial Carcinoma to improve the treatment scenario. Janssen Research and Development is leading the therapeutic market with its Urothelial Carcinoma drug candidates in the most advanced stage of clinical development.

The Leading Companies in the Urothelial Carcinoma Therapeutics Market Include:

  • 4D pharma plc

  • Abbisko Therapeutics

  • AstraZeneca

  • Bayer

  • Helsinn/QED Therapeutics

  • Ikena Oncology

  • Incyte Corporation

  • Infinity Pharmaceuticals

  • Inovio Pharmaceuticals

  • Janssen Research and Development

  • Kyowa Kirin, Inc.

  • MedPacto

  • Pfizer

  • Prestige BioPharma

  • RemeGen

  • RemeGen

  • Seagen

  • TARIS Biomedical

  • Vyriad

And many others

Urothelial Carcinoma Emerging and Marketed Drugs Covered in the Report Include:

  • Pemazyre (pemigatinib): Incyte

  • Cetrelimab: Janssen Research and Development

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Urothelial Carcinoma Current Treatment Patterns

4. Urothelial Carcinoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Urothelial Carcinoma Late Stage Products (Phase-III)

7. Urothelial Carcinoma Mid-Stage Products (Phase-II)

8. Urothelial Carcinoma Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Urothelial Carcinoma Discontinued Products

13. Urothelial Carcinoma Product Profiles

14. Key Companies in the Urothelial Carcinoma Market

15. Key Products in the Urothelial Carcinoma Therapeutics Segment

16. Dormant and Discontinued Products

17. Urothelial Carcinoma Unmet Needs

18. Urothelial Carcinoma Future Perspectives

19. Urothelial Carcinoma Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @


Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your pharmaceutical portfolio today @ Pharmaceutical Portfolio Management Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States